Telo Genomics is a pioneering biotechnology company focused on applying its 3D telomere analytics to predict disease risk in multiple myeloma (MM). TeloView®, the company’s ground-breaking single-cell analysis platform, utilizes a proprietary machine learning algorithm to quantify genomic signals of disease that unleashes disease progression predictive power. TeloView® is the only technology that examines six telomere to fully characterize the 3D architecture of cellular nuclei. TeloView® interrogation of telomeres enables dynamic quantification of genomic changes.